Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Ilse Novak-Hofer"'
Publikováno v:
BioTechniques, Vol 34, Iss 5, Pp 968-972 (2003)
To develop new recombinant monoclonal antibody fragments for therapy and imaging, it is indispensable to have a simple and easy procedure to handle the eukaryotic expression system for production of proteins in high amounts. Gene amplification techni
Externí odkaz:
https://doaj.org/article/470f3a4a98024d4f828e4bf74c29ce4d
Autor:
P. August Schubiger, Jürgen Grünberg, Simon Mensah Ametamey, Michael Honer, Elisa Garcia-Garayoa, Peter Bläuenstein, Robert Waibel, Ilse Novak-Hofer, Roger Schibli
Publikováno v:
CHIMIA, Vol 58, Iss 10 (2004)
The research and development of smart radiodrugs is the goal of the Center of Radiopharmaceutical Science of ETH, PSI, and USZ. Positron Emission Tomography (PET) allows the non-invasive visualization of biochemical processes within the body. Radiola
Externí odkaz:
https://doaj.org/article/2b83d05dcc27430a8822549722f9e741
Autor:
Robert Waibel, Matthias Brühlmeier, Alain Blanc, Olga Gasser, Raimo Pellikka, Kurt Zimmermann, Rolf Schwarzbach, Elisa Garcia-Garayoa, Peter Bläuenstein, Roger Schibli, Ilse Novak-Hofer, P. August Schubiger
Publikováno v:
CHIMIA, Vol 54, Iss 11 (2000)
Radiopharmaceutical research and development is carried out by the Center for Radiopharmaceutical Science as part of the PSI Life Science Department, the Department of Applied BioSciences at the Swiss Federal Institute of Technology Zürich and the U
Externí odkaz:
https://doaj.org/article/06be5f48b26d422ca5a7bac1e66a9e4f
Autor:
Susan Cohrs, Karin Waldner-Knogler, Alexander Hohn, Ilse Novak-Hofer, Eliane Fischer, Kurt Zimmermann, Jürgen Grünberg, Roger Schibli, Simone Jeger
Publikováno v:
International Journal of Cancer. 130:2715-2721
The L1-cell adhesion molecule (L1-CAM) is highly expressed in various cancer types including ovarian carcinoma but is absent from most normal tissue. A chimeric monoclonal antibody, chCE7, specifically binds to human L1-CAM and exhibits anti-prolifer
Autor:
Eliane Fischer, P. August Schubiger, Susan Cohrs, Alexandra Friedli, Jürgen Grünberg, Ilse Novak-Hofer, Kurt Ballmer-Hofer, Roger Schibli
Publikováno v:
The International Journal of Biochemistry & Cell Biology. 41:1572-1580
A soluble form of the L1 cell adhesion molecule (sL1) is released from various tumor cells and can be found in serum and ascites fluid of uterine and ovarian carcinoma patients. sL1 is a ligand for several Arg-Gly-Asp (RGD)-binding integrins and can
Autor:
Ilse Novak-Hofer
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 22:175-184
Monoclonal antibodies directed against the L1 cell adhesion molecule were shown recently to inhibit growth of target tumor cells in vitro and the growth of tumor cells in vivo in nude mice. The biologic functions of L1 in tumor cells, which include g
Autor:
Daniela Gast, Michael Honer, Achim Krüger, P. August Schubiger, Gerhard Moldenhauer, Jürgen Grünberg, Ilse Novak-Hofer, Peter Altevogt, Verena Gschwend, Matthias J.E. Arlt
Publikováno v:
Cancer Research. 66:936-943
The L1 cell adhesion molecule is implicated in the control of proliferation, migration, and invasion of several tumor cell types in vitro. Recently, L1 overexpression was found to correlate with tumor progression of ovarian carcinoma, one of the most
Publikováno v:
Journal of Biological Chemistry. 279:31149-31156
The L1 cell adhesion molecule and its soluble form are tumor-associated proteins and potential markers for tumor staging as well as targets for therapeutic intervention. Soluble L1 is produced by metalloprotease-mediated ectodomain shedding of L1. We
Autor:
Ilse Novak-Hofer, August P. Schubiger
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 29:821-830
The application of the beta particle-emitting nuclide 67Cu in radioimmunotherapy is reviewed. The production of the nuclide is outlined, and different production modes are discussed with an emphasis on cyclotron production. A short survey of copper c
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 16:457-467
Radioimmunotherapy of cancer utilizes anti-tumor antibodies or antibody fragments conjugated to radionuclides to deliver radiation selectively to tumors. However, radiolabeled proteins deposit radioactivity in normal organs that metabolize or conserv